Atovaquone / Proguanil Glenmark

Atovaquone / Proguanil Glenmark is a combination medication used for malaria prevention and treatment. This oral medication is manufactured by Glenmark Arzneimittel Gmbh and is suitable for adults and children.

Atovaquone / Proguanil Glenmark is primarily used for the prevention and treatment of malaria, a mosquito-borne disease caused by parasites. It is often prescribed for travelers to areas where malaria is common. This medication works by interfering with the growth of parasites in the red blood cells.

Common effects of Atovaquone / Proguanil Glenmark may include nausea, vomiting, diarrhea, and headache. Some users might experience abdominal pain or loss of appetite. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

Atovaquone / Proguanil Glenmark should be used with caution in individuals with severe kidney disease or metabolic disorders. It is important to follow the prescribed dosage and complete the full course of treatment. This medication should be stored at room temperature and kept out of reach of children.

Atovaquone / Proguanil Glenmark may interact with certain medications, including antacids, metoclopramide, and drugs that affect liver enzymes. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol should be avoided while using this medication.